- Akome’s next-generation, patent-pending psychedelic drug formulation, AKO002 which it believes work synergistically in the treatment of Alzheimer’s
- Akome’s data analysis reveals evidence that psychedelics promote neuroplasticity and neurogenesis
- Akome is continuing to develop its AKO002 psychedelic drug formulation
- Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market
- Core One Labs Inc. (COOL) opened trading at C$0.84 per share
Core One Labs (COOL) newly acquired subsidiary Akome Biotech is developing a psychedelic drug formulation for the treatment of Alzheimer’s Disease.
Akome’s next-generation, patent-pending psychedelic drug formulation, AKO002, contains the psychedelic compound psilocybin and a plant bioactive which are believed to work synergistically in the treatment of Alzheimer’s.
A patent application for AKO002 has been filed with the United States Patent and Trademark Office.
Alzheimer’s is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and, eventually, the ability to carry out the simplest tasks.
The hippocampus, a key structure in learning and retaining information, is particularly vulnerable to Alzheimer’s, including increased inflammation, and one of the earliest parts of the brain to be affected by the disease.
Current approaches to treating Alzheimer’s focus mainly on treating the symptoms of the disease. Available drugs do not change the underlying disease process. There are no disease-modifying treatments for Alzheimer’s.
Akome’s data analysis and mapping reveal anecdotal evidence that psychedelics have positive effects on the promotion of neuroplasticity and neurogenesis and act as agonists at serotonin receptors that appear in high concentrations in regions of the brain that are vulnerable to Alzheimer’s, such as the hippocampus.
Additionally, psychedelics have been shown to have potent anti-inflammatory properties. Akome’s plant bioactive seems to work in a complementary way with the psilocybin compound, as it has several mechanisms of action including β-amyloid reduction and increased cerebral blood flow.
Akome will continue to develop on its initial data mapping, and analysis of its bioactive-psilocybin, as it prepares for the next stage of its novel AKO002 psychedelic drug formulation and its advancement for the treatment of Alzheimer’s Disease.
“Akome’s novel drug formulation for the treatment of Alzheimer’s could be a revolutionary development for the world of neurological science, and a life changer for the millions of people who are suffering from this devastating disease. We are very excited at the prospect of this drug formulation, as it reaches a relatively untapped patient base for psychedelic treatment.” stated Joel Shacker CEO of Core One Labs.
Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic-assisted psychotherapy.
Core One Labs Inc. (COOL) opened trading at C$0.84 per share.